Current Treatment Options in Neurology

, Volume 10, Issue 4, pp 271–284

Low-grade gliomas in adults

  • Sandeep Mittal
  • Mark C. Szlaczky
  • Geoffrey R. Barger

Opinion statement

Making treatment decisions for patients with infiltrating low-grade gliomas (LGGs) is challenging. Patients frequently present with seizures and usually have little or no neurologic deficit. In this younger and relatively well patient population, despite the potential for significant morbidity, we believe that surgical resection, radiation therapy, and chemotherapy each play an important role in the optimal management of these tumors. Randomized clinical trials have begun to address some of the many questions about prognosis, natural history, and treatment, but most questions have yet to be answered. We believe that, when possible, a maximal surgical resection consistent with preservation of neurologic function should be performed, even though it is likely that no randomized clinical trial will ever be done to demonstrate a survival advantage for this approach. External beam radiation therapy is most often given to a total dose of 50.4 or 54 Gy in 1.8-Gy fractions. The role of chemotherapy is less certain, but a growing body of evidence suggests that temozolomide, a generally well-tolerated drug, is active in the treatment of LGGs. In recent years, loss of heterozygosity of chromosome 1p and 19q, as well as silencing of the MGMT gene, have been identified as promising predictors of response to adjuvant therapy in gliomas. Although randomized trials have not yet shown a survival benefit for early radiation therapy or chemotherapy, one study by the European Organisation for Research and Treatment of Cancer did show an improvement in time to tumor progression with the earlier use of radiation therapy. In addition, a trial by the Radiation Therapy Oncology Group (soon to be analyzed and reported) is comparing radiation alone with radiation followed by a year (six cycles) of standard-dose PCV chemo therapy (procarbazine, CCNU, and vincristine); this trial may shed light on the use of chemotherapy in conjunction with radiation therapy for the initial treatment of LGGs. Because patients remain at risk for tumor progression for the remainder of their lives, we recommend lifelong follow-up with MRI scans, even for patients without documented tumor regrowth over long intervals. To give clinicians a more solid basis for guiding therapy recommendations, we encourage participation in large cooperative group clinical trials.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds): WHO Classification of Tumours of the Central Nervous System. Lyon: IARC; 2007.Google Scholar
  2. 2.
    Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479–489.PubMedGoogle Scholar
  3. 3.
    Schwartzbaum JA, Fisher JL, Aldape KD, Wrensch M: Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006, 2:494–503.PubMedCrossRefGoogle Scholar
  4. 4.
    Duffau H, Capelle L: Preferential brain locations of lowgrade gliomas. Cancer 2004, 100:2622–2626.PubMedCrossRefGoogle Scholar
  5. 5.
    Farrell CJ, Plotkin SR: Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin 2007, 25:925–946.PubMedCrossRefGoogle Scholar
  6. 6.
    Wessels PH, Weber WE, Raven G, et al.: Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol 2003, 2:395–403.PubMedCrossRefGoogle Scholar
  7. 7.
    Pignatti F, van den Bent M, Curran D, et al.: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002, 20:2076–2084.PubMedCrossRefGoogle Scholar
  8. 8.
    Henson JW, Gaviani P, Gonzalez RG: MRI in treatment of adult gliomas. Lancet Oncol 2005, 6:167–175.PubMedCrossRefGoogle Scholar
  9. 9.
    White ML, Zhang Y, Kirby P, Ryken TC: Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas? AJNR Am J Neuroradiol 2005, 26:784–790.PubMedGoogle Scholar
  10. 10.
    Danchaivijitr N, Waldman AD, Tozer DJ, et al.: Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008, 247:170–178.PubMedCrossRefGoogle Scholar
  11. 11.
    Guillevin R, Menuel C, Duffau H, et al.: Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas. J Neurooncol 2008, 87:181–187.PubMedCrossRefGoogle Scholar
  12. 12.
    Herholz K, Coope D, Jackson A: Metabolic and molecular imaging in neuro-oncology. Lancet Neurol 2007, 6:711–724.PubMedCrossRefGoogle Scholar
  13. 13.
    Fisher BJ, Naumova E, Leighton CC, et al.: Ki-67: a prognostic factor for low-grade glioma? Int J Radiat Oncol Biol Phys 2002, 52:996–1001.PubMedGoogle Scholar
  14. 14.
    Schiff D, Brown PD, Giannini C: Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007, 69:1366–1373.PubMedCrossRefGoogle Scholar
  15. 15.
    Colman H, Giannini C, Huang L, et al.: Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol 2006, 30:657–664.PubMedCrossRefGoogle Scholar
  16. 16.
    Uematsu M, Ohsawa I, Aokage T, et al.: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol 2005, 72:231–238.PubMedCrossRefGoogle Scholar
  17. 17.
    Jenkins RB, Blair H, Ballman KV, et al.: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006, 66:9852–9861.PubMedCrossRefGoogle Scholar
  18. 18.
    Aldape K, Burger PC, Perry A: Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 2007, 131:242–251.PubMedGoogle Scholar
  19. 19.
    Mariani L, Deiana G, Vassella E, et al.: Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol 2006, 24:4758–4763.PubMedCrossRefGoogle Scholar
  20. 20.
    Kaloshi G, Benouaich-Amiel A, Diakite F, et al.: Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007, 68:1831–1836.PubMedCrossRefGoogle Scholar
  21. 21.
    Okamoto Y, Di Patre PL, Burkhard C, et al.: Populationbased study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 2004, 108:49–56.PubMedCrossRefGoogle Scholar
  22. 22.
    Everhard S, Kaloshi G, Criniere E, et al.: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 2006, 60:740–743.PubMedCrossRefGoogle Scholar
  23. 23.
    Hegi ME, Murat A, Lambiv WL, Stupp R: Brain tumors: molecular biology and targeted therapies. Ann Oncol 2006, 17(Suppl 10):191–197.CrossRefGoogle Scholar
  24. 24.
    Karim A, Maat B, Hatlevoll R, et al.: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 1996, 36:549–556.PubMedGoogle Scholar
  25. 25.
    Shaw E, Arusell R, Scheithauer B, et al.: Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 2002, 20:2267–2276.PubMedCrossRefGoogle Scholar
  26. 26.
    van den Bent MJ, Afra D, de Witte O, et al.: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366:985–990.PubMedCrossRefGoogle Scholar
  27. 27.
    Bauman G, Lote K, Larson D, et al.: Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1999, 45:923–929.PubMedGoogle Scholar
  28. 28.
    Jackson RJ, Fuller GN, Abi-Said D, et al.: Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol 2001, 3:193–200.PubMedCrossRefGoogle Scholar
  29. 29.
    Sanai N, Mirzadeh Z, Berger MS: Functional outcome after language mapping for glioma resection. N Engl J Med 2008, 358:18–27.PubMedCrossRefGoogle Scholar
  30. 30.
    Claus EB, Horlacher A, Hsu L, et al.: Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 2005, 103:1227–1233.PubMedCrossRefGoogle Scholar
  31. 31.
    Nimsky C, Ganslandt O, Buchfelder M, Fahlbusch R: Intraoperative visualization for resection of gliomas: the role of functional neuronavigation and intraoperative 1.5 T MRI. Neurol Res 2006, 28:482–487.PubMedCrossRefGoogle Scholar
  32. 32.
    Pouratian N, Asthagiri A, Jagannathan J, et al.: Surgery Insight: the role of surgery in the management of low-grade gliomas. Nat Clin Pract Neurol 2007, 3:628–639.PubMedCrossRefGoogle Scholar
  33. 33.
    Chang E, Potts M, Keles G, et al.: Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 2008, 108:227–235.PubMedCrossRefGoogle Scholar
  34. 34.
    Berger M, Deliganis A, Dobbins J, Keles G: The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 1994, 74:1784–1791.PubMedCrossRefGoogle Scholar
  35. 35.
    Leighton C, Fisher B, Bauman G, et al.: Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 1997, 15:1294–1301.PubMedGoogle Scholar
  36. 36.
    Nakamura M, Konishi N, Tsunoda S, et al.: Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 2000, 58:108–116.PubMedCrossRefGoogle Scholar
  37. 37.
    Scerrati M, Roselli R, Iacoangeli M, et al.: Prognostic factors in low-grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry 1996, 61:291–296.PubMedCrossRefGoogle Scholar
  38. 38.
    Keles G, Lamborn K, Berger M: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 2001, 95:735–745.PubMedGoogle Scholar
  39. 39.
    Smith J, Chang E, Lamborn K, et al.: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008, 26:1338–1345.PubMedCrossRefGoogle Scholar
  40. 40.
    Shaw EG, Berkey B, Coons MD, et al.: Recurrence following neurosurgeon-determined gross total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg (in press).Google Scholar
  41. 41.
    Papagikos MA, Shaw EG, Stieber VW: Lessons learned from randomised clinical trials in adult low grade glioma. Lancet Oncol 2005, 6:240–244.PubMedCrossRefGoogle Scholar
  42. 42.
    Eyre H, Crowley J, Townsend J, et al.: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas. A Southwest Oncology Group study. J Neurosurg 1993, 78:909–914.PubMedCrossRefGoogle Scholar
  43. 43.
    See SJ, Gilbert MR: Chemotherapy in adults with gliomas. Ann Acad Med Singapore 2007, 36:364–366.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Sandeep Mittal
  • Mark C. Szlaczky
  • Geoffrey R. Barger
    • 1
  1. 1.Department of Neurology, Karmanos Cancer InstituteWayne State UniversityDetroitUSA

Personalised recommendations